Science Corp. Raises $230M as It Races to Bring Its Brain Implant to Market

Why It Matters

PRIMA could become the first market‑ready brain‑computer interface, reshaping treatment for macular degeneration and related blindness. Its success would validate neurotech commercialization and attract further capital to the sector.

Key Takeaways

• $230M Series C funds PRIMA commercialization.
• PRIMA restores reading ability in 80% of trial patients.
• CE‑mark targeted for mid‑2026, starting in Germany.
• Science expands into bio‑hybrid neural interfaces and organ preservation.
• Valuation reaches $1.5B after total $490M funding.

Pulse Analysis

The neurotechnology landscape is shifting from speculative AI investments toward tangible medical applications, and Science Corp. sits at the forefront of this transition. By acquiring and refining Pixium Vision’s PRIMA platform, the company has leveraged existing hardware while adding its own clinical expertise, positioning the implant as a viable therapeutic for advanced macular degeneration. The 80% success rate in visual acuity trials underscores a breakthrough in restoring reading capability, a metric that has long eluded blind‑patient interventions.

Regulatory momentum is critical for neuro‑medical devices, and Science Corp.’s CE‑mark filing signals confidence in meeting European safety standards. Targeting Germany for the initial launch exploits the country’s early‑access pathways, potentially granting patients access years before U.S. FDA clearance. This strategic timing could secure market share against emerging competitors like Synchron and Kernel, who are also racing to commercialize cortical implants but lack a clear ophthalmic use case.

Beyond PRIMA, Science Corp.’s diversification into bio‑hybrid neural interfaces and the Vessel organ‑preservation platform reflects a broader ambition to dominate multiple high‑growth biotech niches. The bio‑hybrid program, which integrates stem‑cell‑derived neurons with a wafer‑like scaffold, aims to create seamless brain‑machine connections, while Vessel’s miniaturized perfusion technology could revolutionize organ transport logistics. Backed by heavyweight investors such as Lightspeed, Khosla, and Y Combinator, the $230 million infusion not only fuels product rollout but also validates confidence in the company’s long‑term vision of merging biology with silicon.